Clinical Trials
37 trialsMorpheus Lung
Hoffmann-La Roche
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
National Cancer Institute (NCI)
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
University of Michigan Rogel Cancer Center
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
BerGenBio ASA
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
Memorial Sloan Kettering Cancer Center
A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Heat Biologics
Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
Pfizer
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
EMD Serono
Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
Eisai Inc.
PIVOT-02
Nektar Therapeutics
PROPEL
Nektar Therapeutics
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
Merck KGaA, Darmstadt, Germany
MK-3475-021
Merck Sharp & Dohme LLC
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Incyte Corporation
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
Sumitomo Pharma Co., Ltd.
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
CanBas Co. Ltd.
CheckMate370
Bristol-Myers Squibb
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
Regeneron Pharmaceuticals
Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
Wake Forest University Health Sciences
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
University of California, Davis
A Study in Non Small Cell Lung Cancer
Eli Lilly and Company
Abraxane and Alimta in Advanced Solid Tumors
University of California, Davis
Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
H. Lee Moffitt Cancer Center and Research Institute
Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer
Washington University School of Medicine
Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
Hoosier Cancer Research Network
Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer
Pfizer
Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer
Eli Lilly and Company
A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer
Eli Lilly and Company
Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer
Eli Lilly and Company
Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)
Eli Lilly and Company
A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients
Eli Lilly and Company
A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy
Eli Lilly and Company
Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer
Eli Lilly and Company